BIND Therapeutics Inc (BIND)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BIND Therapeutics Inc (BIND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013100
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BIND Therapeutics Inc (BIND Therapeutics) is a nanomedicine platform company that develops and commercializes preclinical candidates for cardiovascular disease, cancer and inflammatory disease. The company’s pipeline products include BIND-014, an Accurin that contains the well-established chemotherapeutic agent, docetaxel. It provides AZD-2811, targeted kinase inhibitor, bind-267, and bind-787. BIND Therapeutics also develops oligonucleotides, immuno-oncology, tam targeting, and GC-C. BIND Therapeutic’s medicinal nanoengineering platform overcomes this limitation by adding unprecedented ability to enhance the trafficking of drugs to tumors, while minimizing exposure of healthy tissues. The company operates through its office located in Russia. BIND Therapeutics is headquartered in Cambridge, Massachusetts, the US.

BIND Therapeutics Inc (BIND) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
BIND Therapeutics Secures USD15 Million from Hercules Technology 13
Bind Biosciences Raises US$8.7 Million In Venture Financing 14
Bind Biosciences Secures US$35 Million In Series D Financing Round 15
BIND Biosciences Secures US$4.7 Million In Venture Financing 17
Partnerships 18
BIND Therapeutics Enters Into Licensing Agreement with Yale University 18
BIND Therapeutics Forms Partnership with Affilogic 19
PeptiDream Enters into Research Agreement with BIND Therapeutics 20
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 21
BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 22
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 23
Bind Therapeutics Enters into R&D Agreement with Merck 24
Bind Therapeutics Enters into Research Agreement with Roche for Accurins 25
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 26
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 27
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 28
Licensing Agreements 29
Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 29
Equity Offering 30
BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 30
Bind Therapeutics Completes IPO For US$70.5 Million 32
Asset Transactions 34
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 34
BIND Therapeutics Inc – Key Competitors 36
BIND Therapeutics Inc – Key Employees 37
BIND Therapeutics Inc – Locations And Subsidiaries 38
Head Office 38
Recent Developments 39
Financial Announcements 39
May 09, 2016: BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update 39
Mar 15, 2016: BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS Platform 41
Corporate Communications 43
Jun 17, 2016: BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners 43
May 02, 2016: BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BIND Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BIND Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
BIND Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
BIND Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BIND Therapeutics Secures USD15 Million from Hercules Technology 13
Bind Biosciences Raises US$8.7 Million In Venture Financing 14
Bind Biosciences Secures US$35 Million In Series D Financing Round 15
BIND Biosciences Secures US$4.7 Million In Venture Financing 17
BIND Therapeutics Enters Into Licensing Agreement with Yale University 18
BIND Therapeutics Forms Partnership with Affilogic 19
PeptiDream Enters into Research Agreement with BIND Therapeutics 20
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 21
BIND Therapeutics Enters into Research Agreement with Macrophage Therapeutics 22
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 23
Bind Therapeutics Enters into R&D Agreement with Merck 24
Bind Therapeutics Enters into Research Agreement with Roche for Accurins 25
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 26
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 27
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 28
Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 29
BIND Therapeutics Raises USD21 Million in Public Offering of Shares and Warrants 30
Bind Therapeutics Completes IPO For US$70.5 Million 32
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 34
BIND Therapeutics Inc, Key Competitors 36
BIND Therapeutics Inc, Key Employees 37

★海外企業調査レポート[BIND Therapeutics Inc (BIND)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • George Weston Limited (WN):企業の財務・戦略的SWOT分析
    George Weston Limited (WN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • 3-D Matrix Ltd (7777):企業の財務・戦略的SWOT分析
    3-D Matrix Ltd (7777) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Global Imaging Systems, Inc.:企業のM&A・事業提携・投資動向
    Global Imaging Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Global Imaging Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • ChanTest Corp-製薬・医療分野:企業M&A・提携分析
    Summary ChanTest Corp (ChanTest), a subsidiary of Charles River Laboratories International Inc is a contract research organization that discovers and develops drugs in ion channel and GPCR biology fields. The organization's ion channel products include cell lines and antibodies. Its other products c …
  • Foraco International SA (FAR):企業の財務・戦略的SWOT分析
    Summary Foraco International SA (Foraco) is a provider of drilling solutions for mining, energy, water and infrastructure projects. The company's drilling solutions include hydrogeological drilling, deep directional drilling, metallurgical sampling and large diameter drilling. It provides geological …
  • Cereno Scientific AB (CRNO TO):製薬・医療:M&Aディール及び事業提携情報
    Summary Cereno Scientific AB (Cereno Scientific) is a developer of preventive drugs that normalize the body's own defense system against blood clots. The company develops drugs in the therapeutic area of thrombosis-related cardiovascular diseases. Its lead product candidate CS1 is being developed fo …
  • BENEO GmbH:戦略・SWOT・企業財務分析
    BENEO GmbH - Strategy, SWOT and Corporate Finance Report Summary BENEO GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • China Mengniu Dairy Co Ltd:企業のM&A・事業提携・投資動向
    China Mengniu Dairy Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Mengniu Dairy Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Enercon Services Inc:企業の戦略的SWOT分析
    Enercon Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Applied Maths NV-医療機器分野:企業M&A・提携分析
    Summary Applied Maths NV (Applied Maths), a subsidiary of Biomerieux SA is a healthcare technology company that designs, develops and markets various bioscience software products. The company offers software products which include bionumerics, gelcompar, genemaths xt, kodon and bionumerics 2D. Its b …
  • Singapore Power Limited:戦略・SWOT・企業財務分析
    Singapore Power Limited - Strategy, SWOT and Corporate Finance Report Summary Singapore Power Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ACEA Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary ACEA Biosciences Inc (ACEA) is a biotechnology company that concentrates on the development and commercialization of innovative cell analysis instrumentation for life science research and clinical diagnostics. The company's products include impedance-based, label-free, and real-time cell ana …
  • Basellandschaftliche Kantonalbank:企業の戦略・SWOT・財務分析
    Basellandschaftliche Kantonalbank - Strategy, SWOT and Corporate Finance Report Summary Basellandschaftliche Kantonalbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Bharat Sanchar Nigam Ltd:企業の戦略的SWOT分析
    Bharat Sanchar Nigam Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報
    Summary Eris Lifesciences Ltd (Eris Lifesciences) is a health care products and service provider. The company offers glimepride, telmisertan, methylcobalamin and combinations, vitamin d, rabeprazole, olmesartan, mecobalamin colecalciferol, teneligliptin, rosa canina extract, cilnidipine, atorvastati …
  • Haemonetics Corp (HAE):企業の財務・戦略的SWOT分析
    Haemonetics Corp (HAE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • DuluxGroup Ltd:企業の戦略・SWOT・財務情報
    DuluxGroup Ltd - Strategy, SWOT and Corporate Finance Report Summary DuluxGroup Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sprint Corporation:企業の戦略・SWOT・財務情報
    Sprint Corporation - Strategy, SWOT and Corporate Finance Report Summary Sprint Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Societe BIC (BB):企業の財務・戦略的SWOT分析
    Societe BIC (BB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Jordan International Insurance Company (JIJC):企業の財務・戦略的SWOT分析
    Jordan International Insurance Company (JIJC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆